Diabetes mellitus and the liver cirrhosis;Diabetes mellitus a jaterní cirhóza

Vnitrni Lekarstvi

Volumn 57, Issue 4, 2011, Pages 368-371

  Fejfar, Tomáš ^a   Safka V ^b   Jirkovsky V ^a   Stefankova J ^b   Hulek P ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Fakulty Hradec Králové ^*  (Czech Republic)

Author keywords

Diabetes mellitus; Liver cirrhosis

Indexed keywords

ARTICLE; DIABETES MELLITUS; HUMAN; LIVER CIRRHOSIS;

DIABETES COMPLICATIONS; HEMOCHROMATOSIS; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER CIRRHOSIS;

EID: 79955888519     PISSN: 0042773X     EISSN: 18017592     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Bianchi G, Marchesini G, Zoli M et al. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 1994; 20: 119-125. (Pubitemid 24196500)
2. Lai MS, Hsieh MS, Chiu YH et al. Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology 2006; 43: 1295-1302.
3. Donadon V, Balbi M, Mas MD et al. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010; 30: 750-758.
4. Horák J. Genetická hemochromatóza. In: Ehrmann J, Hůlek P et al (eds). Hepatologie. 1. vyd. Praha: Grada 2010: 339-345.
5. DuBois S, Kowdley V. Review article: targeted screening for hereditary haemochromatosis in high-rise groups. Aliment Pharmacol Ther 2004; 20: 1-14.
6. Aytug S, Reich D, Sapiro LE et al. Impaired IRS-1/PI3-kinase signalling in patients with HCV: a mechanism for increase prevalence of type 2 diabetes. Hepatology 2003; 38: 1384-1392.
7. Alaei M, Negro R. Hepatitis C virus and glucose and lipid metabolism. Diabetes Metab 2008; 34: 692-700.
8. Romeo-Gómez M, Fernández-Rodriguez CM, Andrare RJ at al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008; 48: 721-727.
9. Donadon V, Balbi M, Ghersetti M et al. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 2009; 15: 2506-2511.
10. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009; 69: 223-240.
11. Salpeter SR, Greyber E, Pasternak GA et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010; 20: CD002967.
12. Romero-Gómez M, Diago M, Andrade RJ et al. Spanish Treatment of Resistance to Insulin in Hepatitis C Genotype 1 Group. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009; 50: 1702-1708.